Hematology

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Amy Seung outlines her priorities for leading HOPA through evolving therapies, workforce challenges, and expanding pharmacy roles.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.

Pharmacists and clinicians share strategies to streamline training, collaboration, and patient care with BTCEs.

Disease burden, monitoring strategy, and timing of therapy drive CRS risk and management.

Experts discuss immunotherapy overlap, nutrition challenges, and clinical judgment with GLP-1 RA use.

Oncology pharmacists face profound ethical tensions, often without formal training to navigate them.

Experts detail the workflows and decisions behind launching complex bispecific therapies.

Multicenter data suggests dexamethasone may safely replace tocilizumab for low-grade CRS.

ABBV-744 BD2-selective BET inhibitor shows early spleen and symptom gains with manageable cytopenias in a phase 1b trial.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Evidence questions anemia plus thrombocytopenia prognosis in primary myelofibrosis, helping oncology pharmacists refine hematology risk stratification.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.